Buy Stocks Easy | About Us
May 28, 2020
Buy Stocks Easy | Online Stocks

HCM


Buy Hutchison China MediTech Limited Stock (symbol: HCM) Easy Online

Company Name: Hutchison China MediTech Limited

Symbol: HCM

Sector: Health Care

Industry: Major Pharmaceuticals

IPO: 2016

HCM Current Share Price

Today's HCM ( Hutchison China MediTech Limited ) opening price: $25.6100

Yesterday's HCM ( Hutchison China MediTech Limited ) closing price: $24.9200

Hutchison China MediTech Limited Stock ( symbol: HCM ) Price Chart since IPO (2016):

12 Months Hutchison China MediTech Limited Stock ( symbol: HCM ) Price Chart

Popular Questions about Hutchison China MediTech Limited Public Stock ( HCM )

A: Hutchison China MediTech Limited stock symbol (also called stock or share ticker) is HCM

A: Hutchison China MediTech Limited IPO (Initial Public Offering) took place on 2016

A: Hutchison China MediTech Limited's stock (HCM symbol) price at ther IPO (initial Public Offering) was $25.6100

Q: Is HCM stock worth buying at the moment?

A: If you were looking for a long-term investment portfolio and had bought the 'Hutchison China MediTech Limited stock (symbol: HCM) at the beginning of 2019, at the opening share price of $22.7000, with a minimum of $200, by now your shares would be worth $1962 and your profit would be $1762 - SHOW ONLY IF PROFIT.

Buy Hutchison China MediTech Limited Stock Easy Online

Hutchison China MediTech Limited Stock Ticker Price Chart since IPO:





Hutchison China MediTech Limited Stock Price Yesterday



 


Hutchison China MediTech Limited Stock Price – Last Week




 


Hutchison China MediTech Limited Stock Price – Last Month




 


Hutchison China MediTech Limited Stock Value Chart – 12 Months




            

                

                    

                    
                

                
                
Rate this post

                
            

            
            

             

            

        

    



            



    

        

            

                
 Latest Stock News: 

            

        

        



                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/28/1953538/0/en/Chi-Med-s-Elunate-Fruquintinib-Capsules-Included-in-the-National-Reimbursement-Drug-List-in-China.html
                            

                                
Chi-Med’s Elunate® (Fruquintinib Capsules) Included in the National Reimbursement Drug List in China

                                
                                
LONDON, Nov.  28, 2019  (GLOBE NEWSWIRE) -- Hutchison China MediTec...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/25/1951716/0/en/Chi-Med-Announces-Surufatinib-Granted-FDA-Orphan-Drug-Designation-for-Pancreatic-Neuroendocrine-Tumors.html
                            

                                
Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors

                                
                                
LONDON, Nov.  25, 2019  (GLOBE NEWSWIRE) -- Hutchison China MediTec...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/11/1944471/0/en/Chi-Med-Announces-NDA-Acceptance-in-China-for-Surufatinib-in-Non-Pancreatic-Neuroendocrine-Tumors.html
                            

                                
Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic Neuroendocrine Tumors

                                
                                
LONDON, Nov.  11, 2019  (GLOBE NEWSWIRE) -- Hutchison China MediTec...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/17/1930968/0/en/Chi-Med-highlights-publication-of-Phase-II-data-showing-promising-efficacy-for-Savolitinib-in-MET-amplified-gastric-cancers.html
                            

                                
Chi-Med highlights publication of Phase II data showing promising efficacy for Savolitinib in MET-amplified gastric cancers

                                
                                
LONDON, Oct.  17, 2019  (GLOBE NEWSWIRE) -- Hutchison China MediTec...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/10/1927805/0/en/Innovent-and-Chi-Med-Expand-Global-Collaboration-to-Evaluate-the-Combination-of-Sintilimab-and-Surufatinib-in-Solid-Tumors.html
                            

                                
Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors

                                
                                
SUZHOU, China and LONDON, Oct.  10, 2019  (GLOBE NEWSWIRE) -- Innov...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/04/1925138/0/en/Chi-Med-Initiates-an-International-Phase-I-Ib-Trial-of-HMPL-523-in-Patients-with-Advanced-Relapsed-or-Refractory-Lymphoma.html
                            

                                
Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma

                                
                                
LONDON, Oct.  04, 2019  (GLOBE NEWSWIRE) -- Hutchison China MediTec...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/30/1922579/0/en/CK-Hutchison-prices-offering-of-Chi-Med-share-capital-enabling-deconsolidation-and-confirms-its-intention-to-hold-Chi-Med-as-a-strategic-investment-for-the-long-term.html
                            

                                
CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term

                                
                                
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, ...


                            

                        
                    

                


                            

                    


                        
                            http://www.zacks.com/stock/news/542593/hutchison-china-meditech-solutions-enters-oversold-territory
                            

                                
Hutchison China MediTech Solutions Enters Oversold Territory

                                
                                
Hutchison China MediTech has been on a bit of a cold streak lately,...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/29/1922163/0/en/Chi-Med-to-Discuss-Surufatinib-Phase-III-and-U-S-Phase-I-Ib-Efficacy-and-Safety-Data-Presented-at-the-2019-ESMO-Annual-Meeting.html
                            

                                
Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting

                                
                                
– Surufatinib achieved primary endpoint, reducing the risk of progr...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/25/1920387/0/en/Chi-Med-Highlights-Presentation-of-Clinical-Data-from-the-Successful-SANET-ep-Phase-III-Trial-at-ESMO-Annual-Meeting.html
                            

                                
Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting

                                
                                
– Late-Breaking Abstract of the positive SANET-ep Phase III trial o...


                            

                        
                    

                


            
        

    




    
    





	
	  

	  All right reserved Buy Stocks Easy , 2019.